Jubilant Life Sciences has rallied 8% to Rs 192 after the pharmaceutical company said it expects to achieve sustainable growth in revenue and earnings before interest, taxes, depreciation and amortization (EBITDA) margins in the current financial year.
“The company expects 20-22% revenue growth and EBITDA margins sustainable at 20-21% in FY13 backed by higher utilisation of new, expanded and existing capacities in Life Science Ingredients and CMO,” Jubilant said in a filing to the stock exchanges.
Meanwhile, the company reported loss of Rs 64 crore in Q4FY12 after adjusting for Rs 146 crore of exceptional items, mainly due to loss of impairment of assets/ investments in clinical research business in USA. The company had reported a net profit of Rs 62 crore in the corresponding quarter of previous fiscal.
The stock opened at Rs 177 and hit a high of Rs 196 on the Bombay Stock Exchange. A combined 265,348 shares have changed hands on the counter till early noon deals, against an average sub 50,000 shares that were traded daily in past ten trading days on both the exchanges.
